With D PA2024, a recombinant fusion Etoposide Etopophos protein, the antigen contains Lt, the prostate, prostatic acid phosphatase and granulocyte-macrophage colony stimulating factor. The effi ciency of sipuleucel T has been demonstrated in three Phase III trials. Immunotherapy in the hinge for the study of prostate adenocarcinoma treatment in 512 M Nnern with asymptomatic or minimally symptomatic mCRPC was performed, was associated with sipuleucel T with reduced risk of death by 22% and improved median overall survival of 4, 1 month compared to placebo. Based on these data sipuleucel T for the treatment of asymptomatic or minimally symptomatic mCRPC United States is given, but the consent of the Europ European Union is not expected before 2013. The cooperation of t is known and the high complexity were t the administration sipuleucel T as the main reasons why British oncologists felt that they not cooled with this drug in the n Chsten 5 years weight. However, if the collaboration Ts should fall, it would be an attractive drug because it is low toxic. Despite these drawbacks, the results represent an encouraging step with sipuleucel T get ahead of the R The potential of immunotherapy for prostate cancer in general, and clinicians should be based on this concept as a step in the management keep mCRPC. In fact, there are many other immunotherapeutic agents under clinical evaluation Including Lich ProstVac, ipilumumab, and antique Body against PD1, and the results of these studies are expected with big interest em. Taken together, our survey fi ndings indicated by scientific evidence currently available, c, that have the imminent introduction of new therapies for mCRPC a positive impact on the future management of our patients. But our fi ndings also verst RKT the need for clear guidelines to maximize the benefits and sequential Age hrleisten treatments for the best results for weight. In addition, the Erh Increase in CO Ts h Ago anticipated workload and the use of these new agents associated sorgf requires an insurance valid test. THANK Sanofi Aventis has provided educational grant to the co-disposal Ts associated with the implementation of this survey. Sanofi Aventis had no infl uence on the fi ndings of the survey or content or the content of this manuscript. Angela from Corstorphine Kstorfi s Medical Communications Ltd has provided medical writing support for the preparation of this manuscript is available. This support has been found by the British Urological Oncology Promoted. Heather Payne 鈥 S work was supported by the Centre UCLH / UCL Comprehensive Biomedical Research. CONFLICT OF INTEREST Heather Payne visited and new Fees for U Beir-run and served as a consultant for AstraZeneca, Janssen, Johnson & Johnson, Sanofi Aventis, Novartis and Ferring. Amit Bahl hasdeemed a high risk of recurrence have. Locally advanced prostate cancer is usually very high risk.14 The various indications for the use of ADT in these Pazopanib settings and data to support this evidence was discussed previously15 and are described below. Neoadjuvant ADT surgery. In an effort to improve the results for prostate cancer, a number of studies, administration of neoadjuvant ADT prior to radical prostatectomy in M Nnern with prostate cancer have examined the early stages. Many men were randomized to receive short-term ADT vs.